{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:07:03Z","timestamp":1792750023506,"version":"4.5.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/mou.0b013e32835abd4a","type":"journal-article","created":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T13:57:32Z","timestamp":1352987852000},"page":"5-10","source":"Crossref","is-referenced-by-count":132,"title":["Correlation between benign prostatic hyperplasia and inflammation"],"prefix":"10.1097","volume":"23","author":[{"given":"Yakup","family":"Bostanci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kazzazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Momtahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Laze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Djavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210206","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MOU.0b013e32834100ef","article-title":"An algorithm for medical management in male lower urinary tract symptoms.","volume":"21","author":"Djavan","year":"2011","journal-title":"Curr Opin Urol"},{"key":"R3-4-20210206","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MOU.0b013e32834d8e87","article-title":"American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited.","volume":"22","author":"Juliao","year":"2012","journal-title":"Curr Opin Urol"},{"key":"R4-4-20210206","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MOU.0b013e32834100dd","article-title":"Benign prostate hyperplasia: a review of the years progress from bench to clinic.","volume":"21","author":"Donnell","year":"2011","journal-title":"Curr Opin Urol"},{"key":"R5-4-20210206","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1464-410X.2008.07717.x","article-title":"Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials.","volume":"102","author":"Emberton","year":"2008","journal-title":"BJU Int"},{"key":"R7-4-20210206","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.eururo.2007.11.026","article-title":"The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.","volume":"54","author":"Nickel","year":"2008","journal-title":"Eur Urol"},{"key":"R8-4-20210206","first-page":"1202","article-title":"Is benign prostatic hyperplasia (BPH) an immune inflammatory disease Eur U","volume":"51","author":"Kramer","year":"2007","journal-title":"rol"},{"key":"R9-4-20210206","first-page":"25","article-title":"Could inflammation be a key component in the progression of benign prostatic hyperplasia Curr Opin U","volume":"16","author":"Kramer","year":"2006","journal-title":"rol"},{"key":"R10-4-20210206","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.pop.2010.04.004","article-title":"Benign prostatic hyperplasia: current clinical practice.","volume":"37","author":"Djavan","year":"2010","journal-title":"Prim Care"},{"key":"R11-4-20210206","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0302-2838(02)00548-1","article-title":"Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.","volume":"43","author":"Di Silverio","year":"2003","journal-title":"Eur Urol"},{"key":"R12-4-20210206","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0022-5347(17)56980-3","article-title":"Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study.","volume":"121","author":"Kohnen","year":"1979","journal-title":"J Urol"},{"key":"R14-4-20210206","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.exger.2004.12.008","article-title":"Benign prostatic hyperplasia: age-related tissue-remodeling.","volume":"40","author":"Untergasser","year":"2005","journal-title":"Exp Gerontol"},{"key":"R15-4-20210206","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.eursup.2009.11.003","article-title":"Complex mechanisms in prostatic inflammatory response.","volume":"8","author":"Djavan","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"R16-4-20210206","first-page":"171","article-title":"The picture of the prostatic lymphokine network is becoming increasingly complex.","volume":"4","author":"Steiner","year":"2002","journal-title":"Rev Urol"},{"key":"R17-4-20210206","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2605.2009.00972.x","article-title":"Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.","volume":"33","author":"Fibbi","year":"2010","journal-title":"Int J Androl"},{"key":"R19-4-20210206","first-page":"1736","article-title":"Evaluation of prostatitis in autopsied prostates - is chronic inflammation more associated with benign prostatic hyperplasia or cancer J U","volume":"179","author":"Delongchamps","year":"2008","journal-title":"rol"},{"key":"R20-4-20210206","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ucl.2009.07.003","article-title":"Etiology, epidemiology, and natural history of benign prostatic hyperplasia.","volume":"36","author":"Bushman","year":"2009","journal-title":"Urol Clin North Am"},{"key":"R21-4-20210206","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrc2090","article-title":"Inflammation in prostate carcinogenesis.","volume":"7","author":"De Marzo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R22-4-20210206","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1586\/eci.09.37","article-title":"Prostate autoimmunity: from experimental models to clinical counterparts.","volume":"5","author":"Penna","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"key":"R23-4-20210206","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.4049\/jimmunol.0801875","article-title":"Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation.","volume":"182","author":"Penna","year":"2009","journal-title":"J Immunol"},{"key":"R24-4-20210206","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1590\/S1677-55382011000500008","article-title":"Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer.","volume":"37","author":"Pace","year":"2011","journal-title":"Int Braz J Urol"},{"key":"R27-4-20210206","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/00365590500497960","article-title":"Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen.","volume":"40","author":"Kefi","year":"2006","journal-title":"Scand J Urol Nephrol"},{"key":"R28-4-20210206","first-page":"327","article-title":"Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia BJU I","volume":"100","author":"Mishra","year":"2007","journal-title":"nt"},{"key":"R29-4-20210206","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/aje\/kwp406","article-title":"Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.","volume":"171","author":"Schenk","year":"2010","journal-title":"Am J Epidemiol"},{"key":"R30-4-20210206","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/pros.21027","article-title":"Inflammation in benign prostatic hyperplasia: a 282 patients immunohistochemical analysis.","volume":"69","author":"Robert","year":"2009","journal-title":"Prostate"},{"key":"R31-4-20210206","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ucl.2007.09.012","article-title":"Inflammation and benign prostatic hyperplasia.","volume":"35","author":"Nickel","year":"2008","journal-title":"Urol Clin North Am"},{"key":"R32-4-20210206","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eursup.2009.11.002","article-title":"Benign prostatic hyperplasia and its aetiologies.","volume":"8","author":"Briganti","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"R33-4-20210206","first-page":"879","article-title":"Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia Eur Urol S","volume":"8","author":"Robert","year":"2009","journal-title":"uppl"},{"key":"R34-4-20210206","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11918-008-0011-5","article-title":"Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms.","volume":"6","author":"St Sauver","year":"2008","journal-title":"Curr Prostate Rep"},{"key":"R35-4-20210206","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/pros.10084","article-title":"Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.","volume":"52","author":"Kramer","year":"2002","journal-title":"Prostate"},{"key":"R36-4-20210206","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.mehy.2007.08.022","article-title":"Chronic inflammation in benign prostatic hyperplasia: implications for therapy.","volume":"70","author":"Wang","year":"2008","journal-title":"Med Hypotheses"},{"key":"R37-4-20210206","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2011.03.055","article-title":"The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.","volume":"60","author":"De Nunzio","year":"2011","journal-title":"Eur Urol"},{"key":"R38-4-20210206","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4111\/kju.2012.53.3.139","article-title":"Benign prostatic hyperplasia: from bench to clinic.","volume":"53","author":"Yoo","year":"2012","journal-title":"Korean J Urol"},{"key":"R40-4-20210206","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.cellsig.2010.06.014","article-title":"TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells.","volume":"22","author":"Starsichova","year":"2010","journal-title":"Cell Signal"},{"key":"R41-4-20210206","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.coph.2009.06.002","article-title":"Anti-inflammatory drugs antioxidants, and prostate cancer prevention.","volume":"9","author":"Bardia","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"R42-4-20210206","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri2817","article-title":"Prostate cancer as a model for tumour immunotherapy.","volume":"10","author":"Drake","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"R43-4-20210206","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jsbmb.2006.12.065","article-title":"Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).","volume":"103","author":"Adorini","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R45-4-20210206","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0302-2838(03)00368-3","article-title":"BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.","volume":"44","author":"Vela Navarrete","year":"2003","journal-title":"Eur Urol"},{"key":"R46-4-20210206","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/aje\/kwj258","article-title":"Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia.","volume":"164","author":"St Sauver","year":"2006","journal-title":"Am J Epidemiol"},{"key":"R47-4-20210206","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/aje\/kwi299","article-title":"Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms.","volume":"162","author":"Sutcliffe","year":"2005","journal-title":"Am J Epidemiol"},{"key":"R48-4-20210206","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pros.20110","article-title":"Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III).","volume":"62","author":"Rohrmann","year":"2005","journal-title":"Prostate"},{"key":"R49-4-20210206","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/j.1464-410X.2011.10867.x","article-title":"Nonsteroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.","volume":"110","author":"Sutcliffe","year":"2012","journal-title":"BJU Int"},{"key":"R50-4-20210206","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1464-410X.2004.04839.x","article-title":"Risk behaviours and benign prostatic hyperplasia.","volume":"93","author":"Kang","year":"2004","journal-title":"BJU Int"},{"key":"R51-4-20210206","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/01.ju.0000161598.24740.34","article-title":"Benign prostatic hyperplasia cell line viability and modulation of JM-27 by doxazosin and ibuprofen.","volume":"174","author":"Minnery","year":"2005","journal-title":"J Urol"},{"key":"R53-4-20210206","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.eursup.2009.11.005","article-title":"Serenoa repens: the scientific basis for the treatment of benign prostatic hyperplasia.","volume":"8","author":"Habib","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"R54-4-20210206","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G","article-title":"Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia).","volume":"45","author":"Vacherot","year":"2000","journal-title":"Prostate"},{"key":"R55-4-20210206","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.eursup.2009.11.006","article-title":"The role of Serenoa repens in the clinical management of lower urinary tract symptoms due to benign prostatic hyperplasia.","volume":"8","author":"Lowe","year":"2009","journal-title":"Eur Urol Suppl"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0b013e32835abd4a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:09:24Z","timestamp":1620950964000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042307-201301000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0b013e32835abd4a","relation":{},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}